A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Arm 1: Number of Participants Who Experience an Adverse Event (AE)

  Measured over: Up to approximately 28 months

• Arm 1: Number of Participants Who Discontinue Study Treatment Due To an AE

  Measured over: Up to approximately 25 months

• Arm 1: Area Under the Concentration-Time Curve (AUC) of Pembrolizumab

  Measured over: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles; postdose at Cycle 1 and Cycle 8 (a cycle is 21 days)

• Arm 1: Maximum Concentration (Cmax) of Pembrolizumab

  Measured over: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles; postdose at Cycle 1 and Cycle 8 (a cycle is 21 days)

• Arm 1: Minimum Plasma Concentration (Cmin) of Pembrolizumab

  Measured over: Predose at Cycle 1, 2, 4, 8 and every 4 cycles thereafter up to 35 cycles; postdose at Cycle 1 and Cycle 8 (a cycle is 21 days)

• Arm 2: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)

  Measured over: Up to approximately 37 months

Changes Tremor has spotted